Primary pulmonary lymphomas are uncommon, representing
|
|
- Janel Gaines
- 6 years ago
- Views:
Transcription
1 GENERAL THORACIC Primary Pulmonary Lymphoma Brian B. Graham, MD, Douglas J. Mathisen, MD, Eugene J. Mark, MD, and Ronald W. Takvorian, MD Departments of Thoracic Surgery, Pathology, and Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts Background. Primary pulmonary lymphoma is a rare disease. The clinical characteristics, methods of treatment, and outcomes are not well elucidated. Methods. A retrospective review of primary pulmonary lymphoma cases at a single institution from 1990 to 2002 was performed. Results. Eighteen patients were included, with a mean follow-up of 2.9 years. Fourteen patients had mucosaassociated lymphoid tissue (MALT) lymphoma, 2 had large cell transformation of sheet cells in MALT lymphoma, and 1 each had Hodgkin s disease and follicular lymphoma. Computed tomography-guided biopsy was diagnostic in only two of eight attempts. Eleven patients had disease confined to the pulmonary parenchyma, and 7 had parenchymal disease as well as mediastinal lymphadenopathy. Treatment methods included observation only (n 1), surgery only (n 6), surgery plus chemotherapy (n 8), surgery plus radiotherapy (n 1), and surgery plus chemotherapy plus radiotherapy (n 2). Kaplan-Meier estimate of median time to disease recurrence or death was 6 years. Only 1 patient died of disease-related causes. Patients who had bilateral disease were more likely to have recurrent disease or death (p 0.03). Conclusions. A wide range of treatments were used for patients with generally MALT lymphoma, resulting in good outcomes, and recurrent disease was well controlled. (Ann Thorac Surg 2005;80: ) 2005 by The Society of Thoracic Surgeons Primary pulmonary lymphomas are uncommon, representing less than 1% of lung cancers [1], fewer than 1% of malignant lymphomas [2], and accounting for only 3.6% of extranodal lymphomas [3]. The incidence of primary pulmonary lymphoma peaks in the sixth and seventh decades of life, and the ratio of male to female patients is close to 1:1 [4]. Immunosuppression is a known risk factor for the development of lymphoma, and non-hodgkin s lymphoma occurs in at least 2% of all patients with acquired immunodeficiency syndrome a 200-fold higher rate than the general population [5]. Lymphoma occurring in the post-transplant setting has a different but related pathophysiology, associated with acute Epstein-Barr virus infection in the immunosuppressed host [6]. A revised European-American lymphoma (REAL) classification system for lymphoma histology was published in 1994, and is used extensively for all types of lymphoma [7]. The Ann Arbor staging system has been widely used for lymphomas of all types, and is summarized in Table 1 [8].A commonly used set of criteria for primary pulmonary lymphoma proposed by L Hoste and associates [9] is lymphoma with (1) involvement of the lung, lobar, or primary bronchus, with or without mediastinal involvement, and (2) no evidence of extrathoracic lymphoma at the time of diagnosis or for 3 months thereafter. To contribute to the literature available on this subject, a retrospective chart review of patients diagnosed with primary pulmonary lymphoma at the Massachusetts General Hospital was undertaken. Accepted for publication April 5, Address reprint requests to Dr Graham, University of Colorado Health Sciences Center, Campus Box B-177, Denver, CO 80262; brian.graham@uchsc.edu. Patients and Methods The pathology database at the Massachusetts General Hospital was searched for the period of January 1990 to June 2002 using the keywords pulmonary and lymphoma. Eighty patients were initially identified. Patients were excluded if they failed to meet the criteria proposed by L Hoste and colleagues [9] mentioned above, or had lymphoma in the post-transplant setting. The selection criteria resulted in a list of 18 patients, including 1 who had an initial operation in The patient charts were reviewed for presenting signs, symptoms, and radiologic findings, as well as any previous attempted diagnostic procedures. The details of surgery and the latest notes from follow-up were also obtained. The pathology specimens were reviewed (E.J.M.) to confirm the diagnosis of lymphoma, based on cellular atypia, demonstration of monoclonality, restriction of kappa or lambda light chain for B-cell lymphomas, distortion of lymph node architecture, and other standard criteria used in the diagnosis of malignant lymphoma. Several patients (in addition to the 18 reported in this series) who were previously diagnosed with lymphoma were identified on review to have only benign disease. It was recognized that the REAL classification system [7] is fairly sophisticated, and for surgical staging and prognostication can be more detailed than necessary. Consequently, the disease was identified as one of three categories: mucosa-associated lymphoid tissue (MALT) lymphoma, large cell transformation of sheet cells in MALT (a higher grade of MALT lymphoma), or another large cell lymphoma not arising in or associated with MALT, which was then specifically characterized. Examples of photomicrographs of tissue taken from patients in this series are shown in Figures 1 through 4. Pathologic staging was generally unavailable, as many 2005 by The Society of Thoracic Surgeons /05/$30.00 Published by Elsevier Inc doi: /j.athoracsur
2 Ann Thorac Surg GRAHAM ET AL 2005;80: PRIMARY PULMONARY LYMPHOMA Table 1. Ann Arbor Pulmonary Lymphoma Staging System [8] Stage I I-E II II-E III III-E IV Description Involvement of one lymph node group only Involvement of lung parenchyma only (can be bilateral) Involvement of two or more lymph node groups above the diaphragm Involvement of lung parenchyma and lymph nodes above the diaphragm Involvement of lymph node groups on both sides of the diaphragm Involvement of lung parenchyma and lymph nodes below the diaphragm Diffuse involvement of one or more extralymphatic organs or tissues 1249 GENERAL THORACIC patients had incomplete resections without lymph node sampling. Consequently, radiographic staging was performed using the system in Table 1, and defining lymph node involvement as any lymph node with a dimension 1.0 cm or larger. Statistical correlations were tested using Stata 6.0 (StataCorp LP, College Station, TX). Fisher s exact test was used to compare categorical data, and Student s t test was used for continuous data; all tests were doublesided, and a p of 0.05 or less was used as the cutoff for significance. An exemption from informed consent, as this study is a retrospective chart review, was obtained from the Partners Health Care Human Research Committee (the overseeing institutional review board) on February 28, Results The group of 18 patients included 6 men and 12 women, with a mean age of 66.4 years (median, 66 Fig 2. Low-grade lymphoma (hematoxylin and eosin, original magnification, 400). The lymphoma has small dark nuclei. years; range, 36 to 83 years). The mean follow-up was 2.9 years (range, 5 weeks to 13 years). The initial presenting symptoms are listed in Table 2. Four of the patients had no symptoms of lymphoma on initial examination, even in retrospect. Three of these patients had their disease initially discovered on a radiographic study for an unrelated indication. In the fourth asymptomatic patient, lymphoma was an incidental finding on a pathology specimen resected for adenocarcinoma (which was itself incidentally discovered on a chest roentgenogram for another indication). All patients had a chest computed tomography (CT) as part of the preoperative workup. The patient with the incidental finding of pulmonary lymphoma on a pathology specimen did have minor nonspecific findings on chest CT corresponding to the location of the lymphoma. The findings on chest CT from all patients are summarized in Table 3. Fig 1. Low-grade pulmonary lymphoma (hematoxylin and eosin, original magnification, 40). Nodules of lymphoma are arrayed in part along lymphatic pathways. Fig 3. High-grade lymphoma forming a solid nodule (hematoxylin and eosin, original magnification, 40). A nodule of lymphoma beneath the pleura has fibrosis and a discrete edge.
3 GENERAL THORACIC 1250 GRAHAM ET AL Ann Thorac Surg PRIMARY PULMONARY LYMPHOMA 2005;80: Fig 4. High-grade lymphoma with large atypical lymphoid cells (hematoxylin and eosin, original magnification, 100). The lymphoma has large vesicular nuclei of varying shape and prominent nucleoli. Table 3. Radiographic Findings on Chest Computed Tomography (n 18 Patients) Radiographic Finding n (% of Patients) Number of opacities 1 10 (56) 2 4 (22) 2 4 (22) Mass ( 3 cm) 6 (33) Nodule(s) only ( 3 cm) 7 (39) Infiltrate a 3 (17) Consolidation a 4 (22) Bilateral disease 7 (39) Lymph node enlargement (at least 1.0 cm) Mediastinal only 5 (28) Hilar and mediastinal 2 (11) Pleural effusion 4 (22) a The distinction between infiltrate and consolidation is by radiologic criteria. Infiltrates are generally inhomogeneous, patchy, and without distinct borders, whereas consolidations are homogeneous, dense, and distinct. After the chest CT identified a pulmonary lesion, 8 patients had an attempted CT-guided biopsy, of which only 2 (25%) were diagnostic. One patient with a successful biopsy had no further operation, whereas the other had a definitive video-assisted thoracic surgery wedge resection of all known lymphoma. The other 16 patients had diagnostic thoracic operations, which were not planned preoperatively as definitive therapeutic procedures. The primary type of operation for all patients is listed in Table 4. The resulting surgical pathologic examination showed that most patients (n 14; 78%) had MALT lymphoma. An additional 2 patients had large cell transformation of sheet cells in MALT lymphoma, and 1 each had follicular lymphoma and Hodgkin s lymphoma. The patient with Hodgkin s disease is included in this series because preoperative chest CT showed a 5- by 6-cm left upper lobe mass extending into the hilum, with adjacent hilar lymphadenopathy, and it was unclear whether the tumor originated in the lung or mediastinum. The surgical margins were clean with all known disease Table 2. Symptoms on Presentation (n 18 Patients) Symptom n (% of Patients) Pulmonary Cough 9 (50) Dyspnea 7 (39) Chest pain 3 (17) Wheezing 2 (11) Hemoptysis 1 (6) Systemic Fatigue 2 (11) Weight loss 1 (6) Back pain 1 (6) Arm pain 1 (6) Asymptomatic 4 (22) resected in 4 patients; 1 patient had microscopically positive margins, and 11 had gross disease left behind (often in the contralateral chest). One patient s margins are unclear from reviewing the pathologic specimen and operative records. Postoperative workup included staging the disease. As part of this workup, most patients had CT scans of their abdomen and pelvis, and other commonly performed studies included positron emission tomography and gallium scans. In the patients reported in this series, all patients had negative extrathoracic imaging by definition, as they would not meet the criteria for primary pulmonary lymphoma otherwise. On the basis of the chest CT, 11 (61%) of the patients had disease confined to the lung parenchyma (radiographic stage I-E), whereas the other 7 (39%) patients had pulmonary disease and mediastinal lymphadenopathy (radiographic stage II-E). An additional staging study was bone marrow biopsy, performed in 9 patients, which was positive in 1. It was decided to include this patient in the series, although violating the precise requirements for primary pulmonary lymphoma, as marrow involvement was the only manifestation of extrathoracic disease and was diagnosed after the pulmonary disease. After the operation, the majority of patients received adjuvant therapy, as shown in Table 5. No patients received neoadjuvant therapy, as the diagnosis was almost always Table 4. Principal Operation (n 18 Patients) Operation VATS wedge resection 9 Open lobectomy 3 Open wedge resection 3 Mediastinoscopy / Chamberlain 2 CT-guided biopsy only 1 CT computed tomography; surgery. VATS video-assisted thoracoscopic n
4 Ann Thorac Surg GRAHAM ET AL 2005;80: PRIMARY PULMONARY LYMPHOMA Table 5. Adjuvant Therapy (n 18 Patients) Adjuvant Therapy n (%) Chemotherapy 8 (44) Radiotherapy 1 (6) Chemotherapy and radiotherapy 2 (11) No adjuvant therapy 7 (39) 1251 GENERAL THORACIC unknown before the operation. Three patients had chemotherapy only after disease recurrence, and the remainder of patients who received adjuvant therapy had it in the immediate postoperative period. Two patients received combined chemotherapy and radiotherapy: the patient with Hodgkin s disease, and another patient with MALT lymphoma who had respiratory failure in the setting of a postobstructive pneumonia. Two of the patients who received chemotherapy initially required additional chemotherapy later for recurrent disease. The patient who only had a CT-guided biopsy received no subsequent therapy, and had disease stable at follow-up 6 years later by chest CT. Chemotherapy regimens included steroids alone, rituximab, chlorambucil, CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), CVP (cyclophosphamide, vincristine, and prednisolone), and ABVD (Adriamycin, bleomycin, vinblastine, and dacarbazine), as well as combinations of rituximab with other regimens. The long-term outcomes in this series of patients are in listed Table 6, and Kaplan-Meier curves showing overall survival and disease-free survival are in Figures 5 and 6, respectively. One patient was known to have died of disease-related causes; she had a history of congestive heart failure and recent myocardial infarction, and died 1 month after her operation as a result of postoperative sepsis. Potential risk factors for developing the disease were evaluated. Eleven patients were smokers and 6 were nonsmokers (1 patient s smoking status is unknown). Two patients had probable autoimmune diseases: one had type 1 diabetes mellitus, and the other had alopecia totalis. Lactate dehydrogenase levels were measured in 8 patients, and had a mean value of 293 U/L (range, 161 to 534 U/L; normal range, 0 to 210 U/L). An attempt was made to find prognostic indicators that correlated with survival, and the results are shown in Table 7. Higher stage disease, by the Ann Arbor staging system, was associated with statistically not significantly worse outcomes. As might be expected, patients who received adjuvant therapy did worse, likely because their disease required the use of adjuvant therapy, and a Fig 5. Kaplan-Meier curve of overall survival. (MALT mucosaassociated lymphoid tissue; Pts patients.) Table 6. Long-Term Outcome (n 18 Patients) Outcome n (%) Recovered from disease 10 (56) Persistent poor quality of life because of disease 4 (22) Died of disease 1 (6) Died of other causes 2 (11) Died of unknown cause 1 (6) Fig 6. Kaplan-Meier curve of disease-free survival. (MALT mucosa-associated lymphoid tissue; Pts patients.)
5 GENERAL THORACIC 1252 GRAHAM ET AL Ann Thorac Surg PRIMARY PULMONARY LYMPHOMA 2005;80: Table 7. Prognostic Indicators: Factors Increasing the Probability of Disease Recurrence or Death (n 18 Patients) Factor Risk Ratio p Value Received any adjuvant therapy Infinite Bilateral disease Received adjuvant therapy postoperatively Pathology showing high-grade transformation Not microscopically clean surgical margins Stage II-E disease LDH 1.5 upper limit of normal ( 315 U/L) LDH lactate dehydrogenase. subgroup analysis of just those patients who received adjuvant therapy shortly after their operation did not find any detrimental correlation. There was also no correlation between age and disease-free survival (p 0.66). Comment This small series looks at the presentation, treatment, and outcome of 18 patients with primary pulmonary lymphoma, of whom the majority had MALT lymphoma. An additional 2 patients had large cell transformation of sheet cells in MALT lymphoma, which is a higher grade of MALT lymphoma. These lymphomas are, as the abbreviation signifies, lymphomas arising in mucosa-associated lymphoid tissue. Mucosa-associated lymphoid tissue is a general term that includes BALT (bronchus-associated lymphoid tissue) and GALT (gastrointestinal lymphoid tissue). All MALT lymphomas are B-cell lymphomas, often with plasmacytoid differentiation, and most are low grade, but transition to a higher grade occurs in a minority of cases. Mucosa-associated lymphoid tissue lymphoma is generally considered to have a good prognosis at the time of diagnosis, with one study reporting greater than 80% survival at 5 years in 22 patients [10]. The behavior and natural history of MALT lymphoma is similar for disease in different organ systems [10]. The most common location of MALT lymphoma is in the gastric mucosa (associated with Helicobacter pylori infection). The cause of MALT lymphoma is not completely determined, but is frequently associated with chronic inflammation. For example, the pathogenesis of H. pylori infection leading to gastric MALT lymphoma proceeds along the sequence of infection, lymphocyte recruitment, lymphocyte proliferation, genetic transformation, and malignancy [11]. It has been proposed that a chronic inflammatory origin such as infection, smoking, or autoimmune disease may play a role in the development of pulmonary MALT lymphoma [12]. Of the 16 patients in this series with MALT lymphoma, 9 were smokers, although both patients with high-grade disease were nonsmokers. Two patients had histories of probable autoimmune diseases, and none had a previously diagnosed chronic pulmonary disease or human immunodeficiency virus infection. The incidence of pulmonary MALT lymphoma may be increasing, and is most likely associated with more aggressive evaluation and treatment of all types of lung cancer. Previously when a patient was diagnosed with a large lung mass or bilateral disease, aggressive therapy was not indicated. A small subset of these patients would have very slowly progressive disease, and such miracle cases would live far beyond the expected median survival. In actuality, these patients may have had a lung cancer such as lymphoma, which grows very slowly and is either benign or mildly malignant. As the treatment for all types of lung cancer has improved, physicians are more likely to precisely evaluate all lung lesions and identify the rare lymphomas. Bilateral disease is more suggestive of pulmonary lymphoma, as the differential diagnosis is narrowed to lymphoma, nonmalignant pulmonary disease, metastatic cancer, metachronous primary cancers, or a unilateral process affecting both sides such as bronchoalveolar carcinoma [13]. Another cause of the increased incidence of pulmonary lymphoma may be an increased use of imaging studies (such as whole-body CT scans) in asymptomatic patients. These studies can pick up lung lesions that are benign or mildly malignant, and would have otherwise remained asymptomatic. Three of the patients in this series had their otherwise asymptomatic lymphomas found on imaging studies for unrelated indications. The diagnosis of primary pulmonary lymphoma may be made by any one of a number of different procedures. In this series, CT-guided biopsy of the pulmonary lesion was only successful 25% of the time. Other studies have reported utility with bronchoalveolar lavage [14], but bronchoalveolar lavage alone does not allow the morphologic analysis necessary to make a specific diagnosis. Diagnostic operative procedures range from lymph node biopsy to wedge biopsy or lobectomy. After MALT lymphoma has been diagnosed, appropriate staging should be performed to rule-out extrathoracic disease. The first step is a CT scan of the chest, abdomen, and pelvis to look for lymphadenopathy, masses, or splenic enlargement. Radiotracer imaging with positron emission tomography or gallium is generally less helpful, as there may be little radiotracer uptake in low-grade disease [15]. Extranodal lymphoma also may involve the bone marrow [11, 16], so a bone marrow biopsy is often indicated. In this series, bone marrow biopsy was performed in 9 patients, and was positive in 1 patient with large cell transformation in MALT lymphoma (who otherwise had stage I-E disease). Other useful tests for staging are lactate dehydrogenase and 2 -microglobulin levels to indicate the burden of disease [10], although in this series lactate dehydrogenase was not a useful prognostic indicator for the 8 patients who were tested. After staging the patient, the next step is deciding whether adjuvant therapy is indicated. Frequently the diagnostic biopsy (by wedge resection or lobectomy) resects the entire lesion. If the pathologic diagnosis is MALT lymphoma without evidence of higher-grade transforma-
6 Ann Thorac Surg GRAHAM ET AL 2005;80: PRIMARY PULMONARY LYMPHOMA tion and staging finds no disease elsewhere, a complete resection may be considered definitive, and no further therapy is required. If there is residual disease, disease in the contralateral chest, or extrathoracic disease, either chemotherapy or radiotherapy (if the lesion is localized) may be considered. In this series, bilateral disease (independent of pathologic diagnosis) was associated with a higher risk of disease recurrence or death, warranting more aggressive therapy. Mild chemotherapy regimens include rituximab, chlorambucil, and CVP (cyclophosphamide, vincristine, and prednisolone). A patient with recurrent disease may be considered for more aggressive chemotherapy regimens, including CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or ABVD (Adriamycin, bleomycin, vinblastine, and dacarbazine). Rituximab may be added to any of the other regimens. The specific example of a patient who has the diagnosis of localized MALT lymphoma made by CT-guided biopsy may choose to have any one or a combination of definitive resection, chemotherapy, or radiotherapy, all of which seem to be equally effective at preventing recurrence [17]. An alternative in an asymptomatic patient with localized low-grade disease diagnosed by CT-guided biopsy is observation only, as performed in 1 patient in this series, reserving treatment for possible future progression of disease based on symptoms or radiographic progression. This patient has remained asymptomatic and her disease stable by annual chest CT. Previous series have mentioned in passing a few patients who received no specific treatment [18], and a published group of 3 patients in Singapore with low-grade small lymphocytic lymphoma were all alive and doing well a mean of 20 months after diagnosis [19]. Even if patients have had definitive surgical treatment, they should be referred to a medical oncologist both to ensure that the staging is adequate with no disease elsewhere, and to follow the patient for a long time, as this indolent disease may recur after many years [17, 20]. Follow-up studies looking for recurrence may include chest roentgenogram or chest CT. The prognosis for patients with primary pulmonary lymphoma is generally quite good. One large series of 70 patients reported a 94% survival at 5 years for low-grade primary pulmonary lymphoma, and a median survival of 3 years for high-grade disease [18]. Another series with 48 patients reported a 68% 5-year survival for primary pulmonary MALT lymphoma and a 65% 5-year survival for non-malt lymphoma [21]. In this series, the Kaplan-Meier estimate of median time to disease recurrence or death was 6 years. Furthermore, no patients died after disease recurrence, as all patients with disease recurrence were treated and their disease suppressed with chemotherapy. Overall, primary pulmonary lymphoma is a rare lung cancer, but the prognosis is good. Many patients are asymptomatic at the time of diagnosis. Treatment options for localized disease include observation, definitive resection, chemotherapy, or radiotherapy. Surgical cure is not possible if there is diffuse or multifocal disease, but patients still have a favorable prognosis, particularly if large cell transformation has not occurred. The median time to disease recurrence or death in this series is 6 years, comparable with previously published studies, and patients who did have disease recurrence were all treated successfully with chemotherapy. Patients can have poor outcomes in the unusual circumstance when the disease presents in a fulminant manner with extensive extrathoracic disease, or if there is significant comorbidity. References Miller DL, Allen MS. Rare pulmonary neoplasms. Mayo Clin Proc 1993;68: Rosenbery SA, Diamond HD, Jaslowitz B, et al. Lymphosarcoma: a review of 1269 cases. Medicine 1961;40: Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer 1972;29: Li G, Hansmann ML, Zwingers T, et al. Primary lymphomas of the lung: morphological, immunohistochemical and clinical features. Histopathology 1990;16: Rabkin CS, Yellin F. Cancer incidence in a population with a high prevalence of infection with human immunodeficiency virus type 1. J Natl Cancer Inst 1994;86: Nalesnik MA. Clinicopathologic characteristics of posttransplant lymphoproliferative disorders. Recent Results Cancer Res 2002;159: Harris NL, Jaffe ES, Stein H, et al. A revised European- American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin s Disease Staging Classification. Cancer Res 1971;31: L Hoste RJ, Fillipa DA, Lieberman PH, Bretsky S. Primary pulmonary lymphoma. A clinicopathologic analysis of 36 cases. Cancer 1984;54: Thieblemont C, de la Fouchardiere A, Coiffier B. Nongastric mucosa-associated lymphoid tissue lymphomas. Clin Lymphoma 2003;3: Kahl BS. Update: gastric MALT lymphoma. Curr Opin Oncol 2003;15: Nicholson AG, Wotherspoon AC, Diss TC, et al. Reactive pulmonary lymphoid disorders. Histopathology 1995;26: Kjeldsberg KM, Oh K, Murray KA, Cannon G. Radiographic approach to multifocal consolidation. Semin Ultrasound CT MR 2002;23: Davis WB, Gadek JE. Detection of pulmonary lymphoma by bronchoalveolar lavage. Chest 1987;91: Hoffmann M, Kletter K, Becherer A, Jager U, Chott A, Raderer M. 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology 2003;64: Kent SA, Variakojis D, Peterson LC. Comparative study of marginal zone lymphoma involving bone marrow. Am J Clin Pathol 2002;117: Zinzani PL, Tani M, Gabriele A, et al. Extranodal marginal zone B-cell lymphoma of MALT-type of the lung: single-center experience with 12 patients. Leuk Lymphoma 2003;44: Cordier JF, Chailleux E, Lauque D, et al. Primary pulmonary lymphomas: a clinical study of 70 cases in nonimmunocompromised patients. Chest 1993;103: Toh HC, Ang PT. Primary pulmonary lymphoma clinical review from a single institution in Singapore. Leuk Lymphoma 1997;27: Yoshino T, Ichimura K, Mannami T, et al. Multiple organ mucosa-associated lymphoid tissue lymphomas often involve the intestine. Cancer 2001;91: Ferraro P, Trastek VF, Adlakha H, Deschamps C, Allen MS, Pairolero PC. Primary non-hodgkin s lymphoma of the lung. Ann Thorac Surg 2000;69: GENERAL THORACIC
Thoracic surgeons are seldom confronted with hematologic
Role of Surgery in the Treatment of Primary Pulmonary B-Cell Lymphoma Frederic Vanden Eynden, MD, Elie Fadel, MD, Marc de Perrot, MD, MS, Vincent de Montpreville, MD, Sacha Mussot, MD, and Philippe Dartevelle,
More informationConjunctival CD5+ MALT lymphoma and review of literatures
ISPUB.COM The Internet Journal of Pathology Volume 8 Number 2 Conjunctival CD5+ MALT lymphoma and review of literatures M Fard Citation M Fard. Conjunctival CD5+ MALT lymphoma and review of literatures.
More informationClinico-Pathologic Conferences Early Bronchus-Associated Lymphoid Tissue Lymphoma Diagnosed with Immunoglobulin Heavy Chain Molecular Testing
Canadian Respiratory Journal Volume 2016, Article ID 7056035, 4 pages http://dx.doi.org/10.1155/2016/7056035 Clinico-Pathologic Conferences Early Bronchus-Associated Lymphoid Tissue Lymphoma Diagnosed
More informationMantle Cell Lymphoma Mainly Involving Thoracic Lesions: Two Case Reports
CASE REPORT Mantle Cell Lymphoma Mainly Involving Thoracic Lesions: Two Case Reports Makoto Kosaka 1, Tomonobu Koizumi 1, Toshirou Fukushima 1, Yousuke Wada 1, Toshihiko Agatsuma 1, Toshiki Yokoyama 1,
More informationLYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center
LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center Lymphoma is cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make up and store cells
More informationLarge cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s
Non Hodgkin s Lymphoma Introduction 6th most common cause of cancer death in United States. Increasing in incidence and mortality. Since 1970, the incidence of has almost doubled. Overview The types of
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationSuperior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis
ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD
More information2007 ANNUAL SITE STUDY HODGKIN S LYMPHOMA
2007 ANNUAL SITE STUDY HODGKIN S LYMPHOMA SUSQUEHANNA HEALTH David B. Nagel, M.D. April 11, 2008 Hodgkin s lymphoma was first described by Thomas Hodgkin in 1832. It remained an incurable malignancy until
More informationDuring past decades, because of the lack of knowledge
Staging and Classification of Lymphoma Ping Lu, MD In 2004, new cases of non-hodgkin s in the United States were estimated at 54,370, representing 4% of all cancers and resulting 4% of all cancer deaths,
More informationOBJECTIVES. Solitary Solid Spiculated Nodule. What would you do next? Case Based Discussion: State of the Art Management of Lung Nodules.
Organ Imaging : September 25 2015 OBJECTIVES Case Based Discussion: State of the Art Management of Lung Nodules Dr. Elsie T. Nguyen Dr. Kazuhiro Yasufuku 1. To review guidelines for follow up and management
More informationAdam J. Hansen, MD UHC Thoracic Surgery
Adam J. Hansen, MD UHC Thoracic Surgery Sometimes seen on Chest X-ray (CXR) Common incidental findings on computed tomography (CT) chest and abdomen done for other reasons Most lung cancers discovered
More informationBronchogenic Carcinoma
A 55-year-old construction worker has smoked 2 packs of ciggarettes daily for the past 25 years. He notes swelling in his upper extremity & face, along with dilated veins in this region. What is the most
More informationNew lung lesion in a 55 year-old male treated with chemoradiation for non-small cell lung carcinoma
July 2016 New lung lesion in a 55 year-old male treated with chemoradiation for non-small cell lung carcinoma Contributed by: Laurel Rose, MD, Resident Physician, Indiana University School of Medicine,
More informationNon-Hodgkin lymphoma
Non-Hodgkin lymphoma Non-Hodgkin s lymphoma Definition: - clonal tumours of mature and immature B cells, T cells or NK cells - highly heterogeneous, both histologically and clinically Non-Hodgkin lymphoma
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationIndolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital
Indolent Lymphomas Dr. Melissa Toupin The Ottawa Hospital What does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with
More informationTHORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
More informationLymphoma Read with the experts
Lymphoma Read with the experts Marc Seltzer, MD Associate Professor of Radiology Geisel School of Medicine at Dartmouth Director, PET-CT Course American College of Radiology Learning Objectives Recognize
More informationCase Scenario 1. The patient agreed to a CT guided biopsy of the left upper lobe mass. This was performed and confirmed non-small cell carcinoma.
Case Scenario 1 An 89 year old male patient presented with a progressive cough for approximately six weeks for which he received approximately three rounds of antibiotic therapy without response. A chest
More informationLymphomas and multiple myeloma 12/23/2018 1
60 Lymphomas and multiple myeloma 12/23/2018 1 Lymphomas Lymphoma is cancer of the lymphatic system. Lymphomas are subdivided into two main categories: Hodgkin's lymphoma (HL) and non- Hodgkin's lymphoma
More informationNon-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)
Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL) Lymphoid Neoplasms: 1- non-hodgkin lymphomas (NHLs) 2- Hodgkin lymphoma 3- plasma cell neoplasms Non-Hodgkin lymphomas (NHLs) Acute Lymphoblastic Leukemia/Lymphoma
More informationLung Cancer-a primer. Sai Yendamuri, MD Professor and Chair, Dept of Thoracic Surgery,RPCI,Buffalo
Lung Cancer-a primer Sai Yendamuri, MD Professor and Chair, Dept of Thoracic Surgery,RPCI,Buffalo CLINICAL CATEGORIES THE SOLITARY PULMONARY NODULE MULTIPLE PULMONARY NODULES Differential Diagnosis Malignant
More informationUpdate in Lymphoma Imaging
Update in Lymphoma Imaging Victorine V. Muse, MD Lymphoma Update in Lymphoma Imaging Victorine V Muse, MD Heterogeneous group of lymphoid neoplasms divided into two broad histological categories Hodgkin
More informationHodgkin's Lymphoma. Symptoms. Types
Hodgkin's lymphoma (Hodgkin's disease) usually develops in the lymphatic system, a part of the body's immune system. This system carries disease-fighting white blood cells throughout the body. Lymph tissue
More informationRevisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis
Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,
More informationPleural effusion as an initial manifestation in a patient with primary pulmonary monoclonal B-cell lymphocyte proliferative disease
Du et al. Respiratory Research (2018) 19:247 https://doi.org/10.1186/s12931-018-0941-6 LETTER TO THE EDITOR Pleural effusion as an initial manifestation in a patient with primary pulmonary monoclonal B-cell
More informationSlide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
More informationRegression of Advanced Gastric MALT Lymphoma after the Eradication of Helicobacter pylori
Gut and Liver, Vol. 6, No. 2, April 2012, pp. 270-274 CASE REPORT Regression of Advanced Gastric MALT Lymphoma after the Eradication of Helicobacter pylori Soo-Kyung Park, Hwoon-Yong Jung, Do Hoon Kim,
More informationLung hilar Ga-67 uptake in patients with lymphoma following chemotherapy
ORIGINAL ARTICLE Annals of Nuclear Medicine Vol. 18, No. 5, 391 397, 2004 Lung hilar Ga-67 uptake in patients with lymphoma following chemotherapy Emel Ceylan GUNAY,* Bilge Volkan SALANCI,* Ibrahim BARISTA**
More informationNon-Hodgkin Lymphoma in Clinically Difficult Situations
Winship Cancer Institute of Emory University Non-Hodgkin Lymphoma in Clinically Difficult Situations James Armitage, MD Professor, Department of Internal Medicine Joe Shapiro Distinguished Chair of Oncology
More informationBoot Camp Case Scenarios
Boot Camp Case Scenarios Case Scenario 1 Patient is a 69-year-old white female. She presents with dyspnea on exertion, cough, and right rib pain. Patient is a smoker. 9/21/12 CT Chest FINDINGS: There is
More informationA CASE OF PRIMARY THYROID LYMPHOMA. Prof Dr.Dilek Gogas Yavuz Marmara University School of Medicine Endocrinology and Metabolism Istanbul, Turkey
A CASE OF PRIMARY THYROID LYMPHOMA Prof Dr.Dilek Gogas Yavuz Marmara University School of Medicine Endocrinology and Metabolism Istanbul, Turkey 38 year old female She recognized a mass in her right neck
More informationLugano classification: Role of PET-CT in lymphoma follow-up
CAR Educational Exhibit: ID 084 Lugano classification: Role of PET-CT in lymphoma follow-up Charles Nhan 4 Kevin Lian MD Charlotte J. Yong-Hing MD FRCPC Pete Tonseth 3 MD FRCPC Department of Diagnostic
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationLYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG
LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi
More informationIndolent Lymphomas: Current. Dr. Laurie Sehn
Indolent Lymphomas: Current Dr. Laurie Sehn Why does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with current standard
More informationEducational Objectives. Managing Lung Cancer From the Solitary Pulmonary Nodule to Complex Cases: A Multidisciplinary Approach.
Managing Lung Cancer From the Solitary Pulmonary Nodule to Complex Cases: A Multidisciplinary Approach Robert A. Meguid, MD, MPH, FACS Assistant Professor of Cardiothoracic Surgery Surgical Director, Surgical
More informationA Case of Pediatric Plasma Cell Granuloma
August 2001 A Case of Pediatric Plasma Cell Granuloma Nii Tetteh, Harvard Medical School Year IV Our Patient 8 year old male with history of recurrent left lower lobe and lingular pneumonias since 1994.
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationIndium-111 Zevalin Imaging
Indium-111 Zevalin Imaging Background: Most B lymphocytes (beyond the stem cell stage) contain a surface antigen called CD20. It is possible to kill these lymphocytes by injecting an antibody to CD20.
More informationRespiratory Interactive Session. Elaine Borg
Respiratory Interactive Session Elaine Borg Case 1 Respiratory Cytology 55 year old gentleman Anterior mediastinal mass EBUS FNA Case 1 Respiratory Cytology 55 year old gentleman with anterior mediastinal
More informationA c as e of MA LT ly m ph om a of the thy roid ac c om p any in g H as him ot o 's thy roiditis
: 61 3 2001 MALT (MALT om a ) 1, * * =A b s t r a c t = A c as e of MA LT ly m ph om a of the thy roid ac c om p any in g H as him ot o 's thy roiditis T ae Young Lee, M.D., Eun Sang Ryoo, M.D., Il Song
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationExtranodal natural killer/t-cell lymphoma with long-term survival and repeated relapses: does it indicate the presence of indolent subtype?
VOLUME 47 ㆍ NUMBER 3 ㆍ September 2012 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Extranodal natural killer/t-cell lymphoma with long-term survival and repeated relapses: does it indicate the presence
More informationLymphatic system component
Introduction Lymphatic system component Statistics Overview Lymphoma Non Hodgkin s Lymphoma Non- Hodgkin's is a type of cancer that originates in the lymphatic system. It is estimated to be the sixth most
More informationPresentation material is for education purposes only. All rights reserved URMC Radiology Page 1 of 98
Presentation material is for education purposes only. All rights reserved. 2011 URMC Radiology Page 1 of 98 Radiology / Pathology Conference February 2011 Brooke Koltz, Cytopathology Resident Presentation
More informationCASE REPORT. Introduction. Case series reports. J Thorac Dis 2012;4(S1): DOI: /j.issn s003
CASE REPORT Lost in time pulmonary metastases of renal cell carcinoma: complete surgical resection of metachronous metastases, 18 and 15 years after nephrectomy Kosmas Tsakiridis 1, Aikaterini N Visouli
More informationMediastinal Staging. Samer Kanaan, M.D.
Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor
More information7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour
7 Omar Abu Reesh Dr. Ahmad Mansour Dr. Ahmad Mansour -Leukemia: neoplastic leukocytes circulating in the peripheral bloodstream. -Lymphoma: a neoplastic process in the lymph nodes, spleen or other lymphatic
More informationDoppler ultrasound of the abdomen and pelvis, and color Doppler
- - - - - - - - - - - - - Testicular tumors are rare in children. They account for only 1% of all pediatric solid tumors and 3% of all testicular tumors [1,2]. The annual incidence of testicular tumors
More informationUniportal video-assisted thoracoscopic surgery segmentectomy
Case Report on Thoracic Surgery Page 1 of 5 Uniportal video-assisted thoracoscopic surgery segmentectomy John K. C. Tam 1,2 1 Division of Thoracic Surgery, National University Heart Centre, Singapore;
More informationImaging of cardio-pulmonary treatment related damage. Radiotheraphy and Lung
Imaging of cardio-pulmonary treatment related damage Dr. Andrea Borghesi Dr. Emanuele Gavazzi Department of Radiology 2 University of Brescia Radiotheraphy and Lung The goal of radiation therapy (RT) is
More informationClinical Commissioning Policy Proposition: Bendamustine with rituximab for relapsed indolent non-hodgkin s lymphoma (all ages)
Clinical Commissioning Policy Proposition: Bendamustine with rituximab for relapsed indolent non-hodgkin s lymphoma (all ages) Reference: NHS England 1607 1 First published: TBC Prepared by NHS England
More informationThe Spectrum of Management of Pulmonary Ground Glass Nodules
The Spectrum of Management of Pulmonary Ground Glass Nodules Stanley S Siegelman CT Society 10/26/2011 No financial disclosures. Noguchi M et al. Cancer 75: 2844-2852, 1995. 236 surgically resected peripheral
More informationSeptember 2014 Imaging Case of the Month. Michael B. Gotway, MD. Department of Radiology Mayo Clinic Arizona Scottsdale, AZ
September 2014 Imaging Case of the Month Michael B. Gotway, MD Department of Radiology Mayo Clinic Arizona Scottsdale, AZ Clinical History: A 57-year-old non-smoking woman presented to her physician as
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationCase Scenario 1: Thyroid
Case Scenario 1: Thyroid History and Physical Patient is an otherwise healthy 80 year old female with the complaint of a neck mass first noticed two weeks ago. The mass has increased in size and is palpable.
More informationNON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.
More informationobjectives Pitfalls and Pearls in PET/CT imaging Kevin Robinson, DO Assistant Professor Department of Radiology Michigan State University
objectives Pitfalls and Pearls in PET/CT imaging Kevin Robinson, DO Assistant Professor Department of Radiology Michigan State University To determine the regions of physiologic activity To understand
More informationLung. 10/24/13 Chest X-ray: 2.9 cm mass like density in the inferior lingular segment worrisome for neoplasm. Malignancy cannot be excluded.
Lung Case Scenario 1 A 54 year white male presents with a recent abnormal CT of the chest. The patient has a history of melanoma, kidney, and prostate cancers. 10/24/13 Chest X-ray: 2.9 cm mass like density
More informationACHIEVING EXCELLENCE IN ABSTRACTING: LYMPHOMA
ACHIEVING EXCELLENCE IN ABSTRACTING: LYMPHOMA ACHIEVING EXCELLENCE IN ABSTRACTING LYMPHOMA Recoding Audit Performed in 2009 260 cases audited 17 data items audited per case 4420 possible discrepancies
More informationEffective local and systemic therapy is necessary for the cure of Ewing tumor Most chemotherapy regimens are a combination of cyclophosphamide,
Ewing Tumor Perez Ewing tumor is the second most common primary tumor of bone in childhood, and also occurs in soft tissues Ewing tumor is uncommon before 8 years of age and after 25 years of age In the
More informationLimited Role of Bone Marrow Aspiration and Biopsy in the Initial Staging Work-up of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma in Korea
Gut and Liver, Vol. 8, No. 6, November 2014, pp. 637-642 ORiginal Article Limited Role of Bone Marrow Aspiration and Biopsy in the Initial Staging Work-up of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
More informationUpdate on Small Cell Lung Cancer
Welcome to Master Class for Oncologists Session 4: 10:00 AM - 10:45 AM San Francisco, CA October 23, 2009 Speaker: Bruce E. Johnson, MD Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical
More information2012 by American Society of Hematology
2012 by American Society of Hematology Common Types of HIV-Associated Lymphomas DLBCL includes primary CNS lymphoma (PCNSL) Burkitt Lymphoma HIV-positive patients have a 60-200 fold increased incidence
More informationChemotherapy for Adenocarcinoma and Alveolar Cell Carcinoma
Chemotherapy for Adenocarcinoma and Alveolar Cell Carcinoma of the Lung Scott L. Faulkner, M.D., R. Benton Adkins, Jr., M.D., and Vernon H. Reynolds, M.D. ABSTRACT Ten patients with inoperable or recurrent
More informationWell-differentiated Papillary Mesothelioma of the Pleura Diagnosed by Video-Assisted Thoracic Surgical Pleural Biopsy : A Case Report
Showa Univ J Med Sci 25 1, 67 72, March 2013 Case Report Well-differentiated Papillary Mesothelioma of the Pleura Diagnosed by Video-Assisted Thoracic Surgical Pleural Biopsy : A Case Report Yuri TOMITA
More informationLymphoma (Lymphosarcoma) by Pamela A. Davol
Lymphoma (Lymphosarcoma) by Pamela A. Davol Cells derived from the bone marrow that mature and take part in cellular immune reactions are called lymphocytes. When lymphocytes undergo transformation and
More informationLymphoma co existing with Tuberculosis granulomatous
Available online at www.worldscientificnews.com WSN 90 (2017) 265-270 EISSN 2392-2192 SHORT COMMUNICATION Lymphoma co existing with Tuberculosis granulomatous Madeeha Subhan 1, *, Waleed Sadiq 2 1 Ayub
More informationLUNG CANCER. Agnieszka Słowik, MD. Department of Oncology, University Hospital in Cracow Jagiellonian University
LUNG CANCER Agnieszka Słowik, MD Department of Oncology, University Hospital in Cracow Jagiellonian University Epidemiology Most common malignancy worldwide Place of lung cancer among other malignancies
More informationTake Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules
Take Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules Case 1 72 year old white female presents with a nodular thyroid. This was biopsied in
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Ablative therapy, nonsurgical, for pulmonary metastases of soft tissue sarcoma, 279 280 Adipocytic tumors, atypical lipomatous tumor vs. well-differentiated
More informationChief Complain. For chemotherapy
Chief Complain For chemotherapy Present Illness 93.12 Progressive weakness of R t arm for 1 year X-ray: peneative lesion over right proximal humorous Bone scan: multiple increased intake Biopsy of distal
More informationManagement of Neck Metastasis from Unknown Primary
Management of Neck Metastasis from Unknown Primary.. Definition Histologic evidence of malignancy in the cervical lymph node (s) with no apparent primary site of original tumour Diagnosis after a thorough
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationand Strength of Recommendations
ASTRO with ASCO Qualifying Statements in Bold Italics s patients with T1-2, N0 non-small cell lung cancer who are medically operable? 1A: Patients with stage I NSCLC should be evaluated by a thoracic surgeon,
More informationAn Update: Lung Cancer
An Update: Lung Cancer Andy Barlow Consultant in Respiratory Medicine Lead Clinician for Lung Cancer (West Herts Hospitals NHS Trust) Lead for EBUS-Harefield Hospital (RB&HFT) Summary Lung cancer epidemiology
More informationRadiology Pathology Conference
Radiology Pathology Conference Sharlin Johnykutty,, MD, Cytopathology Fellow Sara Majewski, MD, Radiology Resident Friday, August 28, 2009 Presentation material is for education purposes only. All rights
More informationCase Report Pulmonary Hilar Tumor: An Unusual Presentation of Sclerosing Hemangioma
Volume 2016, Article ID 8919012, 4 pages http://dx.doi.org/10.1155/2016/8919012 Case Report Pulmonary Hilar Tumor: An Unusual Presentation of Sclerosing Hemangioma Jui-Hung Hung, Ching Hsueh, Chiung-Ying
More informationCharles Mulligan, MD, FACS, FCCP 26 March 2015
Charles Mulligan, MD, FACS, FCCP 26 March 2015 Review lung cancer statistics Review the risk factors Discuss presentation and staging Discuss treatment options and outcomes Discuss the status of screening
More informationHIV and Malignancy Alaka Deshpande, Himanshu Soni
HIV and Malignancy Alaka Deshpande, Himanshu Soni Emergence of new infectious disease was documented in 1981. Within a short span of time it became a pandemic. It was Acquired Immunodeficiency Syndrome
More informationAdvanced primary pulmonary lymphoepithelioma-like carcinoma: clinical manifestations, treatment, and outcome
Original Article Advanced primary pulmonary lymphoepithelioma-like carcinoma: clinical manifestations, treatment, and outcome Chun-Yu Lin 1,2, Ying-Jen Chen 1,2, Meng-Heng Hsieh 2,3, Chih-Wei Wang 2,4,
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationBronchioloalveolar Carcinoma Mimicking DILD:
Bronchioloalveolar Carcinoma Mimicking DILD: A Case Report 1 Ju Young Lee, M.D., In Jae Lee, M.D., Dong Gyu Kim, M.D. 2, Soo Kee Min, M.D. 3, Min-Jeong Kim, M.D., Sung Il Hwang, M.D., Yul Lee, M.D., Sang
More informationAn Unusual Presentation of Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma as Diffuse Pulmonary Infiltrates with Spontaneous Regression
pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2015;47(4):943-948 Case Report http://dx.doi.org/10.4143/crt.2014.016 Open Access An Unusual Presentation of Pulmonary Mucosa-Associated Lymphoid Tissue
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationRituximab and Combination Chemotherapy in Treating Patients With Non- Hodgkin's Lymphoma
Page 1 of 5 Home Search Study Topics Glossary Search Full Text View Tabular View No Study Results Posted Related Studies Rituximab and Combination Chemotherapy in Treating Patients With Non- Hodgkin's
More informationTesticular relapse of non-hodgkin Lymphoma noted on FDG-PET
Testicular relapse of non-hodgkin Lymphoma noted on FDG-PET Stephen D. Scotti 1*, Jennifer Laudadio 2 1. Department of Radiology, North Carolina Baptist Hospital, Winston-Salem, NC, USA 2. Department of
More informationTracheal Adenocarcinoma Treated with Adjuvant Radiation: A Case Report and Literature Review
Published online: May 23, 2013 1662 6575/13/0062 0280$38.00/0 This is an Open Access article licensed under the terms of the Creative Commons Attribution- NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license),
More informationThoracic Surgery; An Overview
Thoracic Surgery What we see Thoracic Surgery; An Overview James P. Locher, Jr, MD Methodist Cardiovascular and Thoracic Surgery Lung cancer Mets Fungus and TB Lung abcess and empyema Pleural based disease
More informationcame from a carcinoma and in 12 from a sarcoma. Ninety lesions were intrapulmonary and the as the chest wall and pleura. Details of the primary
Thorax 1982;37:366-370 Thoracic metastases MARY P SHEPHERD From the Thoracic Surgical Unit, Harefield Hospital, Harefield ABSTRACI One hundred and four patients are reviewed who were found to have thoracic
More informationDiagnostic challenge: Sclerosing Hemangioma of the Lung. Department of Medicine, Division of Pulmonary and Critical Care, Lincoln Medical and
Diagnostic challenge: Sclerosing Hemangioma of the Lung. S. Arias M.D, R. Loganathan M.D, FCCP Department of Medicine, Division of Pulmonary and Critical Care, Lincoln Medical and Mental Health Center/Weill
More informationLymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC
Lymphoma: What You Need to Know Richard van der Jagt MD, FRCPC Overview Concepts, classification, biology Epidemiology Clinical presentation Diagnosis Staging Three important types of lymphoma Conceptualizing
More informationAggressive Lymphomas - Current. Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre
Aggressive Lymphomas - Current Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre Conflicts of interest I have no conflicts of interest to declare Outline What does aggressive lymphoma
More informationHow I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES
How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES How I Choose First Line Treatment in Follicular Lymphoma in 2017? 1. How do I take into account
More informationLung cancer pleural invasion was recognized as a poor prognostic
Visceral pleural invasion classification in non small cell lung cancer: A proposal on the basis of outcome assessment Kimihiro Shimizu, MD a Junji Yoshida, MD a Kanji Nagai, MD a Mitsuyo Nishimura, MD
More informationPulmonary Sarcoidosis - Radiological Evaluation
Original Research Article Pulmonary Sarcoidosis - Radiological Evaluation Jayesh Shah 1, Darshan Shah 2*, C. Raychaudhuri 3 1 Associate Professor, 2 1 st Year Resident, 3 Professor and HOD Radiology Department,
More informationThe International Association for the Study of Lung Cancer (IASLC) Lung Cancer Staging Project, Data Elements
Page 1 Contents 1.1. Registration... 2 1.2. Patient Characteristics... 3 1.3. Laboratory Values at Diagnosis... 5 1.4. Lung Cancers with Multiple Lesions... 6 1.5. Primary Tumour Description... 10 1.6.
More information